NGC Update Service: August 26, 2013

August 26, 2013 New This Week Guideline Summaries American College of Obstetricians and Gynecologists Fetal growth restriction. This updates a previously published guideline summary. American College of Physicians Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. This updates a previously published guideline summary. Institute for Clinical Systems Improvement Diagnosis and management of chronic obstructive pulmonary disease (COPD). This updates a previously published guideline summary. Management of labor. This updates a previously published guideline summary. North American Spine Society Antibiotic prophylaxis in spine surgery. This updates a previously published guideline summary. Clinical guidelines for diagnosis and treatment of lumbar disc herniation with radiculopathy. Royal College of Obstetricians and Gynaecologists The investigation and management of the small-for-gestational-age fetus. Announcements NGC Spotlight New research review and clinician and consumer guides added! Visit the AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program. Revised Inclusion Criteria NGC has revised its Inclusion Criteria! Visit our updated Inclusion Criteria page to see the new criteria and send us your comments. Health Awareness Topics - August 2013 National Breastfeeding Month (see related guidelines) National Immunization Awareness Month (see related guidelines) Psoriasis Awareness Month (see related guidelines) Conference News The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site. U.S. Food and Drug Administration (FDA) Advisory August 15, 2013: Fluoroquinolone Antibacterial Drugs: FDA has required the drug labels and Medication Guides for all fluoroquinolone antibacterial drugs be updated to better describe the serious side effect of peripheral neuropathy. This serious nerve damage potentially caused by fluoroquinolones may occur soon after these drugs are taken and may be permanent. NGC's Sister Resources Find Innovations and QualityTools classified by disease or clinical category, patient population, setting of care, stage of care, and more in AHRQ's Health Care Innovations Exchange Web site. Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).    How satisfied are you with this e-mail bulletin? Give Us Your Feedback Subscriber Services: Change Your Profile | Unsubscribe | Help Stay Connected: Contact Us | Social Media This email was sent to buzzhairs.health@blogger.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364